Literature DB >> 1575588

Damage to the endothelium in Sjögren's syndrome: lack of correlation with antinuclear antibody titre and presence of antibodies to SSA or SSB autoantigens.

A D Blann1, A C Wainwright, P Emery.   

Abstract

Serum levels of von Willebrand factor antigen (as an index of damage to the endothelium) and tissue antinuclear antibodies and antibodies to SSA (Ro) (which have been associated with vasculitis) and SSB (La) autoantigens were measured in patients with Sjögren's syndrome. Although high levels of all indices were recorded, there were no intercorrelations. This provides evidence that although tissue autoantibodies may be useful in confirming a diagnosis, they have no place in the pathological course of the disease and so may be an epiphenomenon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1575588      PMCID: PMC1004668          DOI: 10.1136/ard.51.3.389

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  10 in total

1.  Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Authors:  J J Belch; A A Zoma; I M Richards; K McLaughlin; C D Forbes; R D Sturrock
Journal:  Rheumatol Int       Date:  1987       Impact factor: 2.631

2.  Factor VIII related antigen in the assessment of vasculitis.

Authors:  A D Woolf; G Wakerley; T B Wallington; D G Scott; P A Dieppe
Journal:  Ann Rheum Dis       Date:  1987-06       Impact factor: 19.103

3.  Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematologic abnormalities, and serologic hyperreactivity.

Authors:  E L Alexander; F C Arnett; T T Provost; M B Stevens
Journal:  Ann Intern Med       Date:  1983-02       Impact factor: 25.391

4.  Factor VIII related antigen: an improved enzyme immunoassay.

Authors:  P E Short; C E Williams; A M Picken; F G Hill
Journal:  Med Lab Sci       Date:  1982-10

5.  Precipitating antibodies to nuclear antigens in systemic vasculitis.

Authors:  D G Scott; R P Skinner; P A Bacon; P J Maddison
Journal:  Clin Exp Immunol       Date:  1984-06       Impact factor: 4.330

6.  Two types of inflammatory vascular disease in Sjögren's syndrome. Differential association with seroreactivity to rheumatoid factor and antibodies to Ro (SS-A) and with hypocomplementemia.

Authors:  R Molina; T T Provost; E L Alexander
Journal:  Arthritis Rheum       Date:  1985-11

7.  Sjögren's syndrome (Sicca syndrome): current issues.

Authors:  H M Moutsopoulos; T M Chused; D L Mann; J H Klippel; A S Fauci; M M Frank; T J Lawley; M I Hamburger
Journal:  Ann Intern Med       Date:  1980-02       Impact factor: 25.391

8.  Anti-Ro (SS-A) and anti-La (SS-B) in patients with Sjögren's syndrome.

Authors:  J B Harley; E L Alexander; W B Bias; O F Fox; T T Provost; M Reichlin; H Yamagata; F C Arnett
Journal:  Arthritis Rheum       Date:  1986-02

9.  Elevation of von Willebrand factor is independent of erythrocyte sedimentation rate and persists after glucocorticoid treatment in giant cell arteritis.

Authors:  A B Federici; R I Fox; L R Espinoza; T S Zimmerman
Journal:  Arthritis Rheum       Date:  1984-09

10.  Factor VIII related antigen in connective tissue disease patients and relatives.

Authors:  J P James; T R Stevens; N D Hall; P J Maddison; N J Goulding; A Silman; S Holligan; C Black
Journal:  Br J Rheumatol       Date:  1990-02
  10 in total
  3 in total

1.  Endothelium damage and von Willebrand factor antigen.

Authors:  P Elling; A Olsson; H Elling
Journal:  Ann Rheum Dis       Date:  1993-01       Impact factor: 19.103

2.  Endothelial cell derived factors in relation to antibodies to SSA or SSB and to endothelial cells in Sjögren's syndrome.

Authors:  S Rantapää-Dahlqvist; T K Nilsson
Journal:  Clin Rheumatol       Date:  1994-06       Impact factor: 2.980

3.  Association of antinuclear antibodies with the risk of intracranial arterial stenosis.

Authors:  Yong-An Sun; Qiu Han; Xiao-He Hou; Xian-Zhen Peng; Lin Tong; Xu Zheng; Jin-Tai Yu; Lan Tan
Journal:  Aging (Albany NY)       Date:  2020-01-21       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.